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The European Brain Council recently unveiled the report “The Value of Treatment for Brain Disorders,” 
which highlights the need for more investment into research on neurological and mental diseases and the 
wide disparities between and within countries relating to treatments, detection, and intervention. More 
than 165 million Europeans are living with brain disorders such as epilepsy, headache, Alzheimer’s 
disease, depression, and multiple sclerosis; the burden on national health budgets is staggering—rising to 
more than 800 billion euro a year in direct and indirect costs such as lost earnings and lost tax revenues. 
Governments and politicians concerned over the cost of headache care for very large numbers of people 
fail to recognize a fundamentally important aspect of the economics of headache disorders: untreated, 
they are a huge financial drain. The high disability leads to massive losses in productivity. The costs of 
treating headache may be high, but would be dwarfed by the savings made from recovered lost work time 
if the resources were allocated to treat headache disorders appropriately [1, 2]. For this reason, 
implementation of good headache healthcare is likely to be cost-saving. Our first priority to improve 
patients’ care should be to demonstrate the value of treating headache in these terms, so that policy will 
recognize the benefits of addressing these healthcare and educational failures. 
The “care pathway” for most European people with headache is a series of dead ends. Many who would 
benefit from professional care find it unavailable, fragmentary, or difficult to access. Where headache 
services exist, they tend to be focused in specialist headache clinics, delivering high-end multidisciplinary 
care with very limited capacity. Such clinics are needed by the minority with complex disorders, but 
cannot serve this purpose when inundated by people who could be effectively treated in primary care—as 
most people needing headache care require neither specialist expertise nor investigations. Contrariwise, 
one in every three people receiving care for migraine in Russia and Spain, and one in every four in 
Luxemburg, does so from specialists [3]. 
Lack of knowledge among healthcare providers is a problem sewn in medical schools: worldwide, only four 
hours are committed to headache disorders in formal undergraduate medical training lasting 4–6 years. 
Poor awareness of headache disorders exists similarly among the general public: headache disorders are 
not perceived by the public as serious as they do not cause death and are not contagious. Consequently, 
headaches are often trivialized as “normal” and seen in those who complain of them as merely an excuse 
to avoid responsibility. On a political level, many governments, even if aware of it, do not acknowledge 
the substantial burden of headache on society. Healthcare for headache obviously comes at a cost: large 
numbers of people need treatments, together with advices on correct usage, and delivery of these 
requires organized healthcare. Good healthcare can greatly reduce the burden of headache, but it 
persists—principally because healthcare systems that should provide this care do not exist or fail to reach 
many who need it [3]. The roots of this failure mostly lie in education failure, at every level, but also in 
limited accessibility to appropriate care. Headache disorders are consequently under-recognized in 
society, under-prioritized in health policy, underdiagnosed in the population, and undertreated in 
healthcare systems. People with headache fail to seek healthcare that is inadequate, and adhere poorly to 
it. 
Policy and system gaps for headache patients result in two principal service gaps: (a) 50% who could and 
should manage themselves do not have the knowledge or receive the educational and practical support to 
do so and therefore misdiagnose, fail to capitalize on potential gains from lifestyle change, under-
medicate or over-medicate, and/or use inappropriate medication, and are at risk of aggravating their 
disorder. (b) Fifty percent who need (would benefit from) structured headache services find they do not 
exist, or are fragmentary with no clear route through, and are provided inexpertly by doctors who are 
uneducated and uninterested and often promote overtreatment with inappropriate drugs. 
Headache care for the large numbers who need it requires structured headache services together with 
public education on how to make correct use of them. Implementation of good headache healthcare is 
likely to be cost-saving and headache patients’ journey can be improved worldwide. The solution is 
implementation of structured headache services through education of professionals at primary care level: 
based in primary care to provide sufficient reach, and supported by educational initiatives that will enable 
to reduce the underdiagnosis of headache disorders. Structured headache services at second or third level 
of care should provide adequate diagnosis and treatments to the more complex situations, such as high-
frequency and chronic headaches or headaches complicated by comorbidities, that require tailored 
multidisciplinary care. 
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